Novel treatment (new drug/intervention; established drug/procedure in new situation)
A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Loss of heterozygosity in SDHB locus on chromosome 1 in a subject with a metastatic papillary type I
    A recent case report in this journal presented the case of a subject with an SDHB mutation who developed a metastatic type II papillary renal cell carcinoma which therapeutically responded to the tyrosine kinase inhibitor, sunitinib 1 2. SDHB germline mutations account for the familial paraganglioma syndrome type 4 (PGL-4) which is characterised by predominantly extra-adrenal paragangliomas with high malignant potential 2. SDHB...
    Show More
    Conflict of Interest:
    None declared.